Clinical effectiveness of imatinib mesylate in cancer treatment is normally compromised
Clinical effectiveness of imatinib mesylate in cancer treatment is normally compromised by its off-target cardiotoxicity. relationship between hypertension and imatinib mesylate-induced cardiotoxicity.12 Recently, the deleterious aftereffect of imatinib mesylate over the heart was shown to be dose-, time-, and age-dependent.14 These authors found mitochondrial impairment and cell death as the mechanisms of myocyte loss and … [Read more…]